Santhera Pharmaceuticals
Clinical trials sponsored by Santhera Pharmaceuticals, explained in plain language.
A specialty pharmaceutical company focused on treatments for rare neuromuscular and pulmonary diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New steroid hope for duchenne boys: safer muscle treatment?
Disease control CompletedThis study tested a drug called vamorolone in 54 boys with Duchenne muscular dystrophy, aged 2 to under 4 years and 7 to under 18 years. The goal was to check safety and how the body processes the drug over 12 weeks. Researchers hope vamorolone may help control the disease with f…
Phase 2 • Sponsor: Santhera Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Healthy volunteers help uncover Vamorolone's enzyme effects
Knowledge-focused CompletedThis study looked at how a medicine called vamorolone affects a key liver enzyme (CYP3A4) that processes many drugs. Eighteen healthy adults took a single dose of midazolam before and after 14 days of vamorolone to see if vamorolone changed how midazolam was handled. The results …
Phase 1 • Sponsor: Santhera Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Early study checks if experimental drug vamorolone affects Body's salt balance
Knowledge-focused CompletedThis completed Phase 1 trial tested whether the experimental drug vamorolone can block the mineralocorticoid receptor, which helps control salt and water balance in the body. Thirty healthy men received a single dose of vamorolone, a positive control drug (eplerenone), or no acti…
Phase 1 • Sponsor: Santhera Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:25 UTC